RTB101 + everolimus

RTB101 + everolimus has been studied in 1 paper since 2021: 1 trial in people. The newest paper, May 6, 2021: “Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on RTB101 + everolimus

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0·1 mg once daily were not associated with a significant reduction in the incidence of laboratory-confirmed RTIs as compared with placebo (data not shown).”
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trialsThe lancet. Healthy longevity2021doi:10.1016/s2666-7568(21)00062-3
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: National Institute on Aging and 1 more
  • 1 of 1 finding with company ties
  • Human trial1

Studies in people

1 study gave RTB101 + everolimus to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on laboratory-confirmed respiratory tract infections

Randomized trial16 weeks1,500 peopleaged at least 65 yearsAdults aged at least 65 yearsThe lancet. Healthy longevity, May 6, 2021

What did studies of RTB101 + everolimus find?

1

Studies of RTB101 + everolimus measured one outcome, laboratory-confirmed respiratory tract infections.

Laboratory-confirmed respiratory tract infections

no changein humans1

1 study
  1. RTB101 + everolimus showed no clear effect on laboratory-confirmed respiratory tract infections in humans.

    “RTB101 10 mg twice daily and RTB101 10 mg in combination with everolimus 0·1 mg once daily were not associated with a significant reduction in the incidence of laboratory-confirmed RTIs as compared with placebo (data not shown).”

    Human trial10 mg plus everolimus 0·1 mg once daily16 weeks

    Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials

    The lancet. Healthy longevity

More on Laboratory-confirmed respiratory tract infections

Latest